Key result
Trial evaluates off-pump injectable pulmonary valve replacement versus on-pump surgery for postoperative blood loss.
Why the study?
Off pump injectable self-expanding pulmonary valve replacement without cardiopulmonary bypass may allow quicker recovery and fewer major complications than conventional on pump valve replacement in patients with congenital heart disease requiring repeated pulmonary valve operations.
Does 'off pump' injectable pulmonary valve replacement reduce post-surgery blood loss compared to 'on pump' conventional pulmonary valve replacement in patients with congenital heart disease?
Does 'off pump' injectable pulmonary valve replacement reduce post-surgery blood loss compared to 'on pump' conventional pulmonary valve replacement in patients with congenital heart disease?
Answers are grounded in this paper and cite their sources.
This trial protocol outlines an investigation into whether off-pump injectable pulmonary valve replacement can reduce post-surgical bleeding and enhance recovery compared to standard on-pump techniques in congenital heart disease.
INTRODUCTION: Patients with congenital heart disease often need repeated operations throughout life to replace the pulmonary valve. Valve replacement with 'injectable' self-expanding valves (which is performed 'off pump' without the use of cardiopulmonary bypass, CPB) may result in quicker recovery and lower risk of major complications than valve replacement with conventional valves (which is performed 'on pump' with the use of CPB). METHODS AND ANALYSIS: We are conducting a multicentre, single-blind randomised controlled trial in patients with congenital heart disease and aged between 12 and 80 years. We will randomise participants in a 1:1 ratio to receive either 'off pump' injectable pulmonary valve replacement or 'on pump' conventional pulmonary valve replacement. The primary outcome will be the difference between the groups with respect to post-surgery blood loss (as measured by chest drain volume) in the first 24 hours. Secondary outcomes will include in-hospital outcomes (intensive care unit stay, inotropic/vasodilator support, chest drain volume in the first 12 hours post-surgery, time of readiness for extubation, blood products used in the first 24 hours post-surgery, time of fitness for discharge, valve and heart function 6 months post-surgery (assessed using cardiovascular magnetic resonance and ECHOCARDIOGRAPHY) and health-related quality of life 6 weeks and 6 months post-surgery. ETHICS AND DISSEMINATION: This trial has been approved by the South West Exeter Research Ethics Committee. Findings will be shared with participating hospitals and disseminated to the academic community through peer reviewed publications and presentation at national and international meetings. Patients will be informed of the results through patient organisations and newsletters to participants. TRIAL REGISTRATION NUMBER: ISRCTN23538073.
No takes yet. Share an insight, caveat, or question.
Heys et al. (2019) studied Congenital heart disease requiring pulmonary valve replacement (n=60). 'Off pump' injectable pulmonary valve replacement (IPVR) vs. 'On pump' conventional pulmonary valve replacement (PVR) was evaluated on Difference between groups with respect to post-surgery blood loss (chest drain volume) in the first 24 hours. 'Off pump' injectable pulmonary valve replacement is being evaluated against conventional 'on pump' replacement for reducing post-surgery blood loss in a randomized controlled trial protocol, and no results are reported yet.
Synapse has enriched 10 related papers. Consider them for comparative context: